Pathologically confirmed cutaneous T-cell lymphoma consistent with mycosis fungoides (MF) based on biopsy done or reviewed at MSKCC
Stage IB or higher MF per ISCL/EORTC criteria; concurrent diagnosis of Sézary syndrome permissible. Patients who have not had prior systemic therapies and refractory/relapsed patients are eligible.
Baseline mSWAT score of at least 10
Stable topical steroids or systemic antipruritic agent (e.g. antihistamines, doxepin, GABA analogs) preceding study entry is permissible, but no new prescribed or over the counter topical or systemic anti-pruritics started post-enrollment
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Ability to provide informed consent
You may not be if
Any oral retinoid therapy for any indication within 3 weeks of the first dose of study drug
Concurrent diagnosis of systemic anaplastic large cell lymphoma (ALCL) or another non-Hodgkin lymphoma
Concurrent diagnosis of additional non-skin malignancy
Pregnancy
Patients unwilling to use two forms of barrier contraception while taking study medication
Receipt of treatment with another investigational device or drug (at present or within 2 weeks of enrollment)
Familial hypertriglyceridemia or other medical conditions in which use of bexarotene would be contraindicated
High likelihood of protocol non-compliance (in opinion of investigator)
Systemic steroids within two weeks of first dose of study drug (patients on systemic steroids for non-disease related conditions will be permitted per investigator discretion)
Prohibited concurrent medications
Gemfibrozil is contraindicated as may increase bexarotene concentrations
Bexarotene is a minor CYP3A4 substrate: avoid strong/moderate CYP3A4 inducers and inhibitors, if possible, but concomitant use is not a contraindication Bexarotene is a moderate CYP3A4 inducer: avoid concurrent administration with CYP3A4 sensitive substrates, for which minimal concentration changes may lead to therapeutic failures of the substrate (e.g. cyclosporine, tacrolimus, sirolimus, quinidine, fentanyl), if possible
Clareo Health | A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides
